16
Sep
Sahajanand Medical Technologies (SMT), a medical devices company with a portfolio of technologically advanced medical devices across vascular and structural heart intervention, announced positive 3-year results from the FIRE Trial, presented at ESC 2025, reaffirming the safety and efficacy of its Supraflex Cruz drug-eluting stent in patients aged 75 years and older with myocardial infarction (MI) and multivessel disease. Supraflex Cruz Stent The FIRE Trial is a study evaluating revascularization strategies in elderly MI patients with multivessel disease. 1,445 patients across 34 centres in Italy, Spain, and Poland were randomized to functionally guided complete revascularization or culprit-only treatment, with Supraflex…
